Lasting immunity and protection from new single-shot, room-temperature stable COVID-19 vaccine

An international collaboration led by Luk H. Vandenberghe, Ph.D., in the Department of Ophthalmology at Mass Eye and Ear, a member of Mass General Brigham, reported that a novel, gene-based COVID-19 vaccine leveraging a unique adeno-associated viral vector (AAV) platform was highly effective at eliciting neutralizing antibody responses and cellular immunity from a single dose. The vaccine provided nonhuman primates near-complete protection against a live SARS-CoV-2 viral challenge led by immunology researcher, Roger Le Grand, Ph.D., of the French Alternative Energies and Atomic Energy Commission (CEA).

With support from Novartis Gene Therapies, the AAVCOVID vaccine was shown to be producible with efficient, scalable, and industry-established manufacturing processes. The investigators further demonstrated that the vaccine product is stable at room-temperature storage conditions for up to one month, facilitating potential future distribution of the vaccine.

Read more of the original article from MedicalXpress

SHARE